Visit Tool
AlphaGenome 2 is an advanced artificial intelligence model developed by Google DeepMind to predict how DNA sequences and genetic variations influence gene activity in different human cell types. Announced on November 11, 2026, it combines genomic AI with single-cell biology to help researchers understand how genetic changes contribute to biological processes and disease.
Unlike traditional genomic analysis tools that examine broad tissue-level patterns, AlphaGenome 2 can investigate how the same genetic variation behaves in specific cell types and biological states. It was trained on more than 107 million individual cell profiles across 68 tissues.
The technology could help scientists investigate genetic diseases, identify important DNA variations, and explore biological mechanisms that were previously difficult to study.
What Is AlphaGenome 2?
AlphaGenome 2 is a next-generation DNA sequence prediction model developed by Google DeepMind. It builds on the original AlphaGenome project, which was introduced in June 2025 to improve understanding of how genetic variations affect gene regulation.
The model focuses on the relationship between DNA sequences, gene expression, and cellular activity.
Every cell in the human body contains essentially the same genetic information, but different cells activate different genes depending on their functions. For example, heart muscle cells and immune cells use different gene-regulation patterns to perform their biological activities.
Understanding these differences is important because certain genetic variations affect only particular cell types.
AlphaGenome 2 addresses this challenge by incorporating information about specific tissues, cell types, and biological conditions when making predictions.
The technology is designed primarily for computational biologists, genetic researchers, biotechnology companies, and scientific institutions rather than everyday AI chatbot users.
How Does AlphaGenome 2 Work?
AlphaGenome 2 uses deep learning to analyze DNA sequences and predict their potential effects on biological processes.
Its architecture combines genomic sequence information with cell-specific experimental data.
1. DNA Sequence Analysis
The first step involves analyzing a DNA sequence to identify patterns associated with biological activity.
DNA contains information that influences how genes function. Some regions provide instructions for producing proteins, while other regions regulate when and where genes become active.
AlphaGenome 2 uses these patterns to predict molecular properties associated with gene regulation.
2. Cell-Specific Conditioning
One of the biggest differences between AlphaGenome and AlphaGenome 2 is how the models handle cell types.
The original model generated predictions across multiple tissues and experiments in parallel.
AlphaGenome 2 uses a conditional approach. Researchers provide a specific biological condition, such as a tissue, cell type, or cellular state, alongside the DNA sequence.
This allows the model to investigate how the same genetic variation behaves differently in different biological environments.
3. Genetic Variant Prediction
A genetic variant is a change in the DNA sequence.
Some variations have little measurable biological impact, while others can influence gene activity, RNA processing, and other molecular processes.
AlphaGenome 2 compares genetic sequence predictions to help researchers understand the potential consequences of these changes.
4. Biological Data Prediction
The model predicts several molecular properties, including gene expression, chromatin accessibility, histone modifications, and DNA methylation.
These predictions help scientists understand how genetic information is regulated inside different cells.
Key Features of AlphaGenome 2 in 2026
Google DeepMind introduced several important improvements with AlphaGenome 2.
1. Single-Cell Biology Integration
The most important feature is its ability to work with cell-specific biological information.
The model was trained using more than 107 million individual cell profiles across 68 tissues, combining human and mouse data.
This helps researchers study genetic effects at a more detailed cellular level rather than relying only on broad tissue averages.
For example, a genetic variation might influence gene expression in one type of immune cell but have little effect in another.
2. Improved Genetic Variant Prediction
AlphaGenome 2 aims to identify genetic variations that influence gene activity more accurately.
According to Google DeepMind, its evaluation on the TenK10K dataset identified 30% of causal variants, compared with 16% for the original AlphaGenome fine-tuned on single-cell data and other specialized tools in the reported comparison.
It also improved the identification of directional gene effects from 23% to 43%.
These results suggest that AlphaGenome 2 can help researchers prioritize genetic variations that deserve further investigation.
However, these figures apply to the reported benchmark and should not be interpreted as universal clinical accuracy.
3. Generalization to New Cell Types
Another important capability is its ability to analyze previously unseen cellular states without retraining.
Researchers can provide a single-cell RNA sequencing dataset containing information about gene activity.
AlphaGenome 2 converts this information into a cell-state representation and uses it to condition its predictions.
This is useful when studying biological conditions that were not directly represented in the original training data.
4. Cross-Modality Data Prediction
Scientific experiments do not always measure every biological property.
For example, a researcher might have gene-expression measurements but lack information about chromatin accessibility.
AlphaGenome 2 supports cross-modality imputation, allowing it to predict certain unmeasured molecular properties from available biological information.
This can help scientists identify missing information and prioritize future laboratory experiments.
5. DNA Methylation Prediction
AlphaGenome 2 also predicts DNA methylation, an important addition to its molecular prediction capabilities.
DNA methylation involves chemical modifications that influence how genes are regulated.
Studying this process can help researchers understand differences in cellular activity and biological development.
6. Disease-Related Genetic Research
The model can investigate how genetic variations influence disease-relevant cells.
Google DeepMind demonstrated its ability to reproduce findings involving a genetic variant associated with inflammatory bowel disease (IBD).
The model identified how a regulatory variation selectively increases ETS2 gene activity in gut macrophages.
This illustrates how cell-specific predictions may help researchers investigate the molecular mechanisms behind complex diseases.
AlphaGenome vs. AlphaGenome 2: What Has Changed?
AlphaGenome 2 builds on the original model but introduces a more detailed approach to understanding cellular differences.
| Feature | AlphaGenome | AlphaGenome 2 |
| Main focus | DNA regulatory prediction | Cell-specific DNA prediction |
| Cell information | Parallel tissue and cell outputs | Conditional cell-state input |
| Single-cell integration | More limited | Advanced integration |
| Genetic variant analysis | Broad molecular predictions | More cell-specific predictions |
| DNA methylation | Not included in the original model’s listed outputs | Included |
| New cell states | Limited condition-specific generalization | Can generalize without retraining |
| Main purpose | Understanding genome regulation | Connecting genetics with cellular biology |
The key improvement is not simply a larger dataset. AlphaGenome 2 changes how biological context is incorporated into predictions.
This allows researchers to investigate more specific questions about where and how genetic variations influence cellular activity.
Real-World Applications of AlphaGenome 2
1. Rare Genetic Disease Research
Researchers often face thousands of possible genetic variations when investigating unexplained diseases.
AlphaGenome 2 can help prioritize candidate variants by predicting their potential molecular effects in relevant cell types.
This may help scientists narrow down which genetic changes deserve additional laboratory investigation.
2. Drug Discovery and Biotechnology
Understanding which genes are affected by particular genetic variations can help researchers investigate biological pathways involved in disease.
Biotechnology teams may use these predictions to explore potential therapeutic targets and identify relevant cellular mechanisms.
However, the model does not independently establish that a drug target is safe or effective.
3. Cancer Research
Cancer development involves genetic changes that can alter normal gene regulation.
AlphaGenome 2 could help researchers investigate how regulatory variations influence gene activity in specific cell populations.
These insights may support studies of cancer-related biological mechanisms.
4. Immune System Research
Immune cells change their activity depending on infections, vaccination, and other biological conditions.
AlphaGenome 2 can investigate how genetic variations behave in different immune-cell states.
Google DeepMind demonstrated this approach using data from a COVID-19 mRNA vaccine study, distinguishing activated immune T cells from resting cells.
5. Human Genetics and Complex Traits
Researchers use genome-wide association studies (GWAS) to identify genetic variations associated with human characteristics and diseases.
However, identifying an association does not automatically explain the biological mechanism.
AlphaGenome 2 can help connect potential causal variants with target genes and relevant cell types, making it useful for further genetic investigation.
How to Access and Use AlphaGenome 2
AlphaGenome 2 is primarily designed for scientific research and computational biology.
Google DeepMind provides access through its AlphaGenome API.
Follow these steps to explore the technology.
Step 1: Visit the Official Website
Open the Google DeepMind AlphaGenome page to explore the model and its research capabilities.
Step 2: Review API Documentation
Visit the official AlphaGenome documentation to understand API access, requirements, and available tools.
Step 3: Obtain Research Access
AlphaGenome 2 is available for non-commercial research through the AlphaGenome API.
Researchers should review the applicable terms and access requirements before using it.
Commercial research access is currently available through a private preview.
Step 4: Prepare Genomic Data
Researchers can prepare relevant DNA sequences and biological information.
For cell-specific predictions, the model can also use single-cell RNA sequencing data to represent previously unseen biological states.
Step 5: Run Predictions
Use the API and official interactive Colab tutorials to explore the model’s capabilities.
Researchers can investigate gene expression, molecular activity, and potential genetic variant effects.
Step 6: Analyze the Results
Review model predictions alongside experimental measurements and established scientific literature.
Computational predictions should be treated as research evidence to investigate, not as proof of a biological or medical conclusion.
AlphaGenome 2 Pricing and Availability in 2026
Unlike commercial AI chatbots that offer standard monthly subscriptions, AlphaGenome 2 is currently distributed primarily through research access.
As of November 11, 2026, Google DeepMind has announced the following availability:
| Access type | Availability | Intended users |
| Non-commercial API | Available | Academic and independent researchers |
| Commercial research | Private preview | Biotechnology and commercial research organizations |
| Interactive Colab tutorials | Available | Researchers and developers |
| Public commercial subscription | No published standard plan | Not currently announced |
Google DeepMind has not published a standard monthly subscription price or public per-token pricing for AlphaGenome 2 in its launch announcement.
Researchers should check the official AlphaGenome API documentation for current access requirements and usage terms.
Advantages and Limitations of AlphaGenome 2
Advantages
- Advanced cell-specific genetic predictions.
- Trained on more than 107 million individual cell profiles.
- Covers 68 tissues.
- Improved identification of gene-expression-related variants.
- Supports previously unseen cellular states.
- Includes DNA methylation prediction.
- Helps connect genetic variations with disease-relevant cells.
- Supports research through an API and interactive tutorials.
Limitations
- Intended for research rather than clinical diagnosis.
- Requires appropriate genomic and biological data.
- Predictions need experimental validation.
- Commercial research access is still limited.
- Complex biological processes cannot be fully explained by DNA predictions alone.
- Performance depends on the quality and relevance of available data.
Most importantly, Google DeepMind states that AlphaGenome and AlphaGenome 2 have not been validated or approved for clinical or diagnostic purposes.
Final Verdict: Why AlphaGenome 2 Matters for AI Research
AlphaGenome 2 combines AI and genomics to help researchers understand how DNA variations affect biological activity. Trained on over 107 million cell profiles, it offers improved genetic variant predictions and supports research into disease mechanisms. While it cannot replace laboratory experiments or clinical expertise, it can help scientists develop better research hypotheses and prioritize discoveries.
Visit Google DeepMind for the latest research and RentaAI for more AI guides, tools, and technology updates.
Frequently Asked Questions About AlphaGenome 2
What is AlphaGenome 2 used for?
AlphaGenome 2 is used to predict how DNA sequences and genetic variations influence gene regulation in specific cell types. It supports research into genetic diseases, human biology, and molecular mechanisms.
Who developed AlphaGenome 2?
Google DeepMind developed AlphaGenome 2. It was announced on November 11, 2026, as the next generation of its original AlphaGenome model.
Is AlphaGenome 2 free to use?
AlphaGenome 2 is available through the API for non-commercial research. However, Google has not published a standard commercial subscription price. Commercial research access is currently in private preview.
What makes AlphaGenome 2 different from AlphaGenome?
The original AlphaGenome predicts molecular properties across multiple tissues and experiments. AlphaGenome 2 uses specific cell types and biological states as inputs, enabling more detailed cell-specific predictions.
Can AlphaGenome 2 diagnose genetic diseases?
No. AlphaGenome 2 is a research tool, not an approved clinical diagnostic system. Its predictions require appropriate scientific and experimental validation.
Does AlphaGenome 2 use single-cell RNA sequencing?
Yes. Researchers can provide single-cell RNA sequencing information to help the model understand previously unseen cellular states and predict biological properties.
